Form 4: Agios Pharmaceuticals Director Jacqualyn Fouse Reports Stock Transaction

Director Jacqualyn Fouse reported a transaction involving Agios Pharmaceuticals common stock on June 13, 2024, according to a Form 4 filing with the SEC.

Summary

• On June 13, 2024, Jacqualyn A Fouse, a director of Agios Pharmaceuticals, reported a transaction involving the company's common stock.
• The transaction involved the vesting of 3,388 restricted stock units, each representing a contingent right to receive one share of Agios Pharmaceuticals common stock.
• Following the transaction, Fouse directly owns 140,784 shares of Agios Pharmaceuticals common stock.
• The restricted stock units were granted on June 13, 2023, and vested in full on June 13, 2024.
• Vested shares will be delivered to Fouse within three business days after vesting.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Positives

• The vesting of restricted stock units indicates confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Key Dates